It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. It is expected Merck will apply for approval by late-2014. Cowen and Co predicted it will bring a billion a year in sales by 2020.
This drug was developed at Merck Frosst in Montreal.
^Gauthier JY, Chauret N, Cromlish W et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett.18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID18226527.CS1 maint: Explicit use of et al. (link)